MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions.

MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions.
复制标题

MEK抑制剂-神经纤维瘤病相关良性和恶性病变的新型靶向治疗。

DOI:
10.1186/s40364-021-00281-0
复制
发表时间:
2021-04-16
期刊:
影响因子:
11.1
通讯作者:
Harder A
Harder A
中科院分区:
医学2区
文献类型:
--
作者:
Harder A

文献摘要

参考文献

被引文献

相似文献

MAP/ERK激酶1和2 (MEK 1/2)抑制剂(MEKi)在几项试验中被研究用于治疗由1型和2型基因(NF1, NF2)的致病性变异引起的病变。这些试验表明,MEKi能够缩小NF1低级别胶质瘤和丛状神经纤维瘤的体积。针对与NF1高发病率相关的其他病变似乎是有希望的。由于在NF2相关病变和恶性肿瘤中涉及多种途径,MEKi也被用于联合治疗。本文综述了MEKi在神经纤维瘤病及相关良恶性病变中的应用现状。
MAP/ERK kinase 1 and 2 (MEK 1/2) inhibitors (MEKi) are investigated in several trials to treat lesions that arise from pathogenic variants of the Neurofibromatosis type 1 and type 2 genes (NF1, NF2). These trials showed that MEKi are capable to shrink volume of low grade gliomas and plexiform neurofibromas in NF1. Targeting other lesions being associated with a high morbidity in NF1 seems to be promising. Due to involvement of multiple pathways in NF2 associated lesions as well as in malignant tumors, MEKi are also used in combination therapies. This review outlines the current state of MEKi application in neurofibromatosis and associated benign and malignant lesions.
DOI: 10.1056/nejmoa1605943
发表时间: 2016-12-29
期刊: The New England journal of medicine
影响因子: --
作者:
Dombi E;Baldwin A;Marcus LJ;Fisher MJ;Weiss B;Kim A;Whitcomb P;Martin S;Aschbacher-Smith LE;Rizvi TA;Wu J;Ershler R;Wolters P;Therrien J;Glod J;Belasco JB;Schorry E;Brofferio A;Starosta AJ;Gillespie A;Doyle AL;Ratner N;Widemann BC
通讯作者: Widemann BC
DOI: 10.1212/01.wnl.0000435744.57038.af
发表时间: 2013-11-19
期刊: NEUROLOGY
影响因子: 9.9
作者:
Dombi, Eva;Ardern-Holmes, Simone L.;Widemann, Brigitte C.
通讯作者: Widemann, Brigitte C.
DOI: 10.1093/neuonc/noz002
发表时间: 2019-04-01
期刊: NEURO-ONCOLOGY
影响因子: 15.9
作者:
Fuse, Marisa A.;Dinh, Christine T.;Fernandez-Valle, Cristina
通讯作者: Fernandez-Valle, Cristina
DOI: 10.1002/ajmg.a.34359
发表时间: 2012-01-01
期刊: American journal of medical genetics. Part A
影响因子: --
作者:
Blakeley, Jaishri O;Evans, D Gareth;Giovannini, Marco
通讯作者: Giovannini, Marco
DOI: 10.1007/s11060-014-1710-0
发表时间: 2015-04-01
影响因子: 3.9
作者:
Goutagny, Stephane;Raymond, Eric;Kalamarides, Michel
通讯作者: Kalamarides, Michel